Clinical trial
Sorafenib With TACE to Treat Hepatocellular Carcinoma
NCT00478374 · University of Bern, Other · Completed
Key facts
| NCT number | NCT00478374 |
|---|---|
| Title | Sorafenib With TACE to Treat Hepatocellular Carcinoma |
| Official title | Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma |
| Acronym | S-TACE |
| Lead sponsor | University of Bern, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | Sorafenib, Transarterial chemoembolisation with doxorubicin |
| Enrollment | 21 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | May 24, 2007 |
| Last update posted | Nov 2, 2010 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: